Pre-made Matuzumab biosimilar ( Whole mAb, anti-EGFR therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-337
Anti-EGFR therapeutic antibody (Pre-made Matuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-EGFR therapeutic antibody (Pre-made Matuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||3c08:HL/5vr9:HL:AB|
|99% SI Structure||5vsi:HL/3c09:HL:CB|
|95-98% SI Structure||None|
|Companies||ImClone Systems;Merck KGaA;Takeda|
|Conditions Discontinued||Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer|